Evidence map›Paper›PMID 30595942›Full record

ArticleJournal of pharmaceutical analysis2018

Detection and determination of undeclared synthetic caffeine in weight loss formulations using HPLC-DAD and UHPLC-MS/MS.

Carine Viana, Gabriela M Zemolin, Thaís R Dal Molin, Luciana Gobo, Sandra Maria Ribeiro, Gabriela C Leal, Gabriela Z Marcon, Leandro M de Carvalho

Open access · goldAbstract read
In one paragraph

Article in Journal of pharmaceutical analysis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Supercritical COACS omega · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Carine VianaGraduate Program in Pharmaceutical Sciences, Federal University of Santa Maria (UFSM), Santa Maria-RS, Brazil.
Gabriela M ZemolinGraduate Program in Pharmaceutical Sciences, Federal University of Santa Maria (UFSM), Santa Maria-RS, Brazil.
Thaís R Dal MolinGraduate Program in Pharmaceutical Sciences, Federal University of Santa Maria (UFSM), Santa Maria-RS, Brazil.
Luciana GoboDepartment of Chemistry, Federal University of Santa Maria (UFSM), Santa Maria-RS, Brazil.
Sandra Maria RibeiroGraduate Program in Pharmaceutical Sciences, Federal University of Santa Maria (UFSM), Santa Maria-RS, Brazil.
Gabriela C LealGraduate Program in Pharmaceutical Sciences, Federal University of Santa Maria (UFSM), Santa Maria-RS, Brazil.
Gabriela Z MarconGraduate Program in Pharmaceutical Sciences, Federal University of Santa Maria (UFSM), Santa Maria-RS, Brazil.
Leandro M de CarvalhoGraduate Program in Pharmaceutical Sciences, Federal University of Santa Maria (UFSM), Santa Maria-RS, Brazil.
Universidade Federal de Santa Maria · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Caffeine is present in products marketed for weight loss, with the purpose of increasing thermogenesis and lipid metabolism. The dosage declared by the product manufacturer, or even its presence, is not always correctly described on the label. This work aimed to investigate the undeclared synthetic caffeine in weight loss formulations by a high-performance liquid chromatography with diode array detection (HPLC-DAD) method. From one hundred products purchased through Brazilian e-commerce, seventeen contained caffeine, either naturally or synthetically added to formulation. The caffeine-containing samples were confirmed by an ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) method, and adulteration was clearly proven in five products. The content highest caffeine contained 448.8 mg per dose. Other irregularities were also found; nevertheless, the most serious was the addition of synthetic drugs without asking the consumers. Additional drugs expose the consumer to more possible side-effects as well as deleterious drug interactions. Intentional adulteration with any unlabeled substance is typically motivated by a desire to increase or alter the claimed effect of the marketed product to gain a commercial advantage.

Indexed as

HPLC-DADUHPLC-MS/MSUndeclared synthetic caffeineWeight loss formulations

Identifiers

PMID30595942
PMCPMC6308025
OpenAlexW2773097564

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.